[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@arcellx Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1173704377363783685.png) @arcellx Arcellx

Arcellx's Chief Scientific Officer, Heba Nowyhed PhD, was named the CSO Award winner at the S.F. Business Times C-Suite Leaders Awards, recognizing her leadership and passion for biotech innovation. The company is also presenting new data at ASH25 from its Imagine-1 study of anito-cel in patients with relapsed or refractory multiple myeloma. Additionally, Arcellx will be attending IMS25, where its medical affairs team will be available to discuss its lead clinical asset.

### Engagements: XXX [#](/creator/twitter::1173704377363783685/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1173704377363783685/c:line/m:interactions.svg)

- X Week XXXXX +1,004%
- X Month XXXXX +142%
- X Months XXXXX +320%
- X Year XXXXX -X%

### Mentions: X [#](/creator/twitter::1173704377363783685/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1173704377363783685/c:line/m:posts_active.svg)

- X Week XX +17%
- X Month XX -XX%
- X Months XX +1,650%
- X Year XX +133%

### Followers: XXX [#](/creator/twitter::1173704377363783685/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1173704377363783685/c:line/m:followers.svg)

- X Week XXX +1.30%
- X Month XXX +2.20%
- X Year XXX +17%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::1173704377363783685/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1173704377363783685/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[finance](/list/finance)  XXXX%

**Social topic influence**
[philosophy](/topic/philosophy) 4.76%, [trust](/topic/trust) 4.76%, [$aclx](/topic/$aclx) #6

**Top accounts mentioned or mentioned by**
[@kitepharma](/creator/undefined) [@biotechtv](/creator/undefined) [@ramielghandour](/creator/undefined) [@ehahematology](/creator/undefined) [@sfbusinesstimes](/creator/undefined) [@ftlive](/creator/undefined) [@hrdotcom](/creator/undefined) [@gileadsciences](/creator/undefined) [@rami](/creator/undefined) [@checkorphan](/creator/undefined) [@stream_rx](/creator/undefined) [@mriramos](/creator/undefined)

**Top assets mentioned**
[Arcellx, Inc. Common Stock (ACLX)](/topic/$aclx)
### Top Social Posts
Top posts by engagements in the last XX hours

"Yesterday evening we announced new positive data from our Phase X pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma demonstrating anito-cel's potential to be a best-in-class treatment option.Anito-cel is partnered with @KitePharma . Read the full press release here: Today at 5:30 p.m. (PT) in Pacific Ballroom Salons 24-26 Ciara Freeman M.D. Ph.D. will present these preliminary results during an oral presentation. #RRMM #AnitoCel #CellTherapy #CancerResearch"  
[X Link](https://x.com/arcellx/status/1866160019135488487)  2024-12-09T16:36Z XXX followers, XXX engagements


"Attending #IMS25 Visit our Medical Affairs team at booth #616 in Hall E to learn more about our lead clinical asset anito-cel in late-stage development for the treatment of patients with relapsed or refractory #multiplemyeloma in collaboration with @KitePharma"  
[X Link](https://x.com/arcellx/status/1968066893362893093)  2025-09-16T21:38Z XXX followers, XXX engagements


"On November X Chief Operating Officer Aileen Fernandes will join industry leaders during the In pursuit of funding how to create a strategy to advance early-stage drug development panel discussion with @ftlive. This conversation will explore strategies on how #biotech companies can secure funding and stand out among competitors. To register: #MedEd"  
[X Link](https://x.com/arcellx/status/1982858078845600072)  2025-10-27T17:13Z XXX followers, XXX engagements


"Were pleased to announce our presentations at #ASH25 new data from our iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma and an analysis of geographic variation and systemic inequities of CAR-T therapy access in multiple myeloma in the U.S. Stop by our Medical Affairs booth to learn more about our novel binder the D-Domain. We are excited to engage with the hematology community and share insights that could help advance patient care in multiple myeloma. #CellTherapy #MultipleMyeloma #RRMM #AnitoCel #CancerResearch #Innovation"  
[X Link](https://x.com/arcellx/status/1985349560701538514)  2025-11-03T14:13Z XXX followers, 1258 engagements


"After leading teams at Fortune XXX companies Chief People Officer Kate Aiken took a leap into the startup world bringing her leadership philosophy with her. In this interview with @HRdotcom Kate discusses how she builds trust and what shaped her as a leader in HR. Read more: #CSuite #ThoughtLeadership"  
[X Link](https://x.com/arcellx/status/1986102205808554003)  2025-11-05T16:04Z XXX followers, XXX engagements


"Happy Thanksgiving At Arcellx we are grateful for the patients and physicians who participate in our clinical trials our amazing team members our partners at @KitePharma/@GileadSciences and our shareholders. Wishing everyone a joyful holiday"  
[X Link](https://x.com/arcellx/status/1994058632569483715)  2025-11-27T15:00Z XXX followers, XXX engagements


"Arcellx will present new iMMagine-1 data at #ASH25. We look forward to engaging with physicians and advocates sharing insights that could help advance patient care in #multiplemyeloma. Read the release: #CellTherapy #RRMM #AnitoCel #CancerResearch #Innovation #MedEd"  
[X Link](https://x.com/arcellx/status/1996233325061530046)  2025-12-03T15:01Z XXX followers, XXX engagements


"Today we announced new positive data from our Phase X pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory #multiplemyeloma. Read the full press release: Anito-cel is partnered with @KitePharma. #CellTherapy #RRMM #AnitoCel #CancerResearch #Innovation #MedEd"  
[X Link](https://x.com/arcellx/status/1997381369865937113)  2025-12-06T19:03Z XXX followers, XXX engagements


"Our Investor Relations event is live A panel of clinician experts are discussing the latest data from the Phase X pivotal iMMagine-1 study in patients with relapsed or refractory multiple myeloma. Tune in: #Investors $ACLX"  
[X Link](https://x.com/arcellx/status/1997472596896763969)  2025-12-07T01:05Z XXX followers, XXX engagements